AstraZeneca Agrees To Buy Alexion Pharma In $39 Bln Cash And Stock Deal

British drug major AstraZeneca Plc. (AZN.L, AZN) agreed to buy Alexion Pharmaceuticals Inc. (ALXN) for $175 per share in cash and stock, valuing the Boston-based company at $39 billion. The deal is expected to close in third-quarter of 2021.